GOTHENBURG, Sweden, April 27 /PRNewswire/ -- Cellectricon, a leading provider of automated screening solutions for drug discovery, today announced its collaboration with BioFocus DPI, a contract research organization with leading expertise in ion channel screening. BioFocus DPI will utilize Cellectricon's Dynaflow(R)HT, a fully automated patch clamp (APC) system, to further increase its electrophysiology-based screening capacity, particularly for fast ligand-gated ion channels.
Cellectricon's unique high throughput microfluidic screening platform allows us to further develop our leading platform for ion channel screening. This collaboration gives us the opportunity to increase the throughput we provide for customers as well as the number of ion channel subtypes we can screen in an electrophysiology-based format, said Dr. Kate Hilyard, VP Biological Sciences, BioFocus DPI.
Cellectricon is very pleased to provide BioFocus DPI with this state-of-the-art enabling technology that enhances their ion channel drug discovery offering, said Jonas Ohlsson, CEO at Cellectricon. BioFocus DPI is a leading service provider in this field, so it is natural that we collaborate on this new high throughput ion channel screening system. We are delighted to join forces with BioFocus DPI to bring this next generation APC system - with unmatched throughput and data quality at a competitive cost - to the market.
About Dynaflow(R)HT System
The Dynaflow(R)HT microfluidic ion channel screening platform is the world's first APC technology enabling high throughput screening of all kinds of ion channels - voltage gated or ligand gated. Fully automated, the Dynaflow(R)HT has a throughput exceeding all existing APC systems - at a very competitive running cost. Rapid compound exchange enables highly complex perfusion protocols, gives superior data quality, and reduces compound usage. The new Dynaflow(R)HT screening platform is developed in close collaboration with leaders in the pharmaceutical industry.
Cellectricon AB, a Swedish biotech company, successfully provides groundbreaking products to the pharmaceutical and biotechnology industries. The company utilizes state-of-the-art interfaces to biological systems by employing novel microfluidic technologies. This enables completely new types of assays and devices with superior performance characteristics and robustness. Cellectricon's products address critical bottlenecks in the drug discovery process and have been adopted by top-reference customers, including nine of the top ten pharmaceutical companies. In 2007, the company increased its annual revenue by almost 50%. In 2008-2009 the company is launching two pioneering large-scale screening platforms developed in close collaboration with leaders in the pharmaceutical industry. Used in pre-clinical pharmaceutical development, the Cellaxess(R)HT System enables high throughput RNAi screening and the Dynaflow(R)HT System greatly advances ion channel drug discovery.
Contact details Jonas Ohlsson, CEO, Phone: +46(0)709-73-47-92, E-mail: email@example.com. Susanne Fagerlund, VP Marketing Communications, Phone: +46(0)31-760-35-15, E-mail: firstname.lastname@example.org.
Contact details: Jonas Ohlsson, CEO, Phone: +46(0)709-73-47-92, E-mail: email@example.com. Susanne Fagerlund, VP Marketing Communications, Phone: +46(0)31-760-35-15, E-mail: firstname.lastname@example.org.